691 related articles for article (PubMed ID: 21895884)
1. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Elmer LW
Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
[TBL] [Abstract][Full Text] [Related]
5. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
[TBL] [Abstract][Full Text] [Related]
12. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
18. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Iansek R; Danoudis M
Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
[TBL] [Abstract][Full Text] [Related]
19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
